Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | MYC | P01106 | 2/20 | 0.52 |
| ▸ | MAX | P61244 | 2/20 | 0.52 |
| ▸ | KCNMA1 | Q12791 | 4/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17775425 | 0.94 | EP300 (0.54) | EP300HIF1AMYCMAXKCNMA1 | |
| SCHEMBL16392543 | 0.92 | MAPT (0.56) | EP300HIF1AMYCMAXKCNMA1 | |
| SCHEMBL16392539 | 0.91 | EP300 (0.52) | EP300HIF1AMYCMAXKCNMA1 | |
| SCHEMBL17775428 | 0.90 | KCNMA1 (0.50) | EP300HIF1AKCNMA1MAPTMEN1 | |
| SCHEMBL16392501 | 0.88 | KCNMA1 (0.56) | EP300HIF1AKCNMA1MAPTMEN1 | |
| SCHEMBL16392516 | 0.88 | KCNMA1 (0.52) | EP300HIF1AKCNMA1MAPTMEN1 | |
| SCHEMBL17775423 | 0.85 | MAPT (0.50) | EP300HIF1AKCNMA1MAPTMEN1 | |
| SCHEMBL17775426 | 0.83 | MAPT (0.55) | EP300HIF1AKCNMA1MAPTMEN1 | |
| SCHEMBL17775424 | 0.81 | MAPT (0.50) | EP300HIF1AKCNMA1MAPTMEN1 | |
| SCHEMBL16392522 | 0.80 | EP300 (0.53) | EP300HIF1AMYCMAXBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145304-A1 | CYSTOBACTAMIDES | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145304-A1 | CYSTOBACTAMIDES | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| WO-2015003816-A2 | CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145304-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, CBS | EP300 3526/4885HIF1A 2049/4885MYC 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.